Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers develop single vaccine for avian influenza and duck enteritis
Duck enteritis virus infects geese, swans and ducks, leading to loss of life in almost 100 per cent of cases.

CRISPR/Cas9 method applied to duck enteritis virus for the first time

Researchers at The Pirbright Institute have used gene editing technology to create a single vaccine for avian influenza and duck enteritis virus (DEV).

Writing in the journal Viruses, the researchers explain how they used a method of CRISPR/Cas9 gene editing to insert protective avian influenza virus genes into DEV. This method allows higher rates of gene insertion and makes the process more efficient.

DEV infects geese, swans and ducks, leading to loss of life in almost 100 per cent of cases. To reduce the impact of DEV, vaccines are used widely and have recently been employed for delivering components of other viruses such as avian influenza.

In SouthEast Asia, domestic duck populations also play a key role in maintaining the reservoir of severe bird flu strains and allow the infection to ‘spillover into chickens’. This makes them important targets for vaccination campaigns.

Like human flu, vaccination against avian flu is complicated by the hundreds of potential strains, with seasonal variations deciding which vaccine should be used. The gene editing technique used by The Pirbright Institute allows for the rapid development of vaccines that can protect against DEV whilst keeping up with the changing circulating flu strains.

“This is the first time this CRISPR/Cas9 method has been applied to duck enteritis virus and is an exciting step forward in the rapid development of bird flu vaccines,” said professor Munir Iqbal. “Vaccines that protect ducks against DEV as well as severe forms of avian flu will reduce production losses for duck farmers, safeguard other poultry species against flu infection and lower the risk of transmission to humans.”

Due to its large genome size, DEV is being increasingly to used to deliver protective genes to birds. The method’s design allows its application to different genres and viruses, opening up the possibility that other diseases can be tackled using this system.

The vaccine is now ready for registration and researchers at Pirbright are now seeking collaborations with pharmaceutical companies to commercialise the vaccine.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.